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Introduction: There is no consensus chemotherapy regimen with con-
current radiotherapy (RT) for inoperable stage IIIA/B non–small-cell lung 
cancer. This trial evaluated pemetrexed with carboplatin (PCb) or cis-
platin (PC) with concurrent RT followed by consolidation pemetrexed.
Methods: In this open-label, noncomparative phase II trial, patients with 
inoperable stage IIIA/B non–small-cell lung cancer (initially all histolo-
gies, later restricted to nonsquamous) were randomized (1:1) to PCb 
or PC with concurrent RT (64–68 Gy over days 1–45). Consolidation 
pemetrexed monotherapy was administered every 21 days for three 
cycles. Primary endpoint was 2-year overall survival (OS) rate.
Results: From June 2007 to November 2009, 98 patients were 
enrolled (PCb: 46; PC: 52). The 2-year OS rate was PCb: 45.4% 
(95% confidence interval [CI], 29.5–60.0%); PC: 58.4% (95% CI, 
42.6–71.3%), and in nonsquamous patients was PCb: 48.0% (95% 
CI, 29.0–64.8%); PC: 55.8% (95% CI, 38.0–70.3%). Median time 
to disease progression was PCb: 8.8 months (95% CI, 6.0–12.6 
months); PC: 13.1 months (95% CI, 8.3–not evaluable [NE]). Median 
OS (months) was PCb: 18.7 (95% CI, 12.9–NE); PC: 27.0 (95% CI, 
23.2–NE). The objective response rates (ORRs) were PCb: 52.2%; 
PC: 46.2%. Grade 4 treatment-related toxicities (% PCb/% PC) were: 
anemia, 0/1.9; neutropenia, 6.5/3.8; thrombocytopenia, 4.3/1.9; and 
esophagitis, 0/1.9. Most patients completed scheduled chemotherapy 
and RT during induction and consolidation phases. No drug-related 
deaths were reported during chemoradiotherapy.
Conclusions: Because of study design, efficacy comparisons can-
not be made. However, both combinations with concurrent RT were 
active and well tolerated.
Key Words: Non–small-cell lung cancer, Pemetrexed, Cisplatin, 
Chemoradiotherapy, Stage III.
(J Thorac Oncol. 2013;8: 1308-1316)
Approximately 30% of patients with non–small-cell lung cancer (NSCLC) have unresectable stage IIIA/B disease 
at diagnosis.1 The standard of care for patients with good per-
formance status is chemoradiotherapy.1,2 Surgical resection 
after chemoradiotherapy does not improve overall survival 
(OS).3 Because the 5-year survival rate for unresectable stage 
IIIA/B disease is only 25%,4 improvements are needed in 
chemoradiotherapy regimens.
Pemetrexed is a multitargeted antifolate.5 It has radio-
sensitizing activity in cultured cells and xenografts6–9 and has 
been tested in combination with radiotherapy (RT) and plati-
num in clinical trials.10–17 These trials have shown the feasi-
bility of combining pemetrexed/platinum with RT in patients 
with locally advanced NSCLC.
The safety profile of pemetrexed, its approved use with 
cisplatin in first-line nonsquamous NSCLC,18,19 and its utility in 
the maintenance setting20 suggest that pemetrexed may be used 
not only with chemoradiation but may also be safe and effec-
tive as consolidation therapy after concurrent chemoradiation.
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On the basis of this rationale, a phase I–II trial was 
designed to test pemetrexed/carboplatin (PCb) or pemetrexed/
cisplatin (PC) with concurrent RT followed by pemetrexed 
consolidation in patients with favorable-prognosis inoper-
able stage IIIA/B NSCLC. The phase I portion of this trial 
established the maximum tolerated and phase II doses of 
pemetrexed with either carboplatin or cisplatin given during 
RT, followed by pemetrexed consolidation.21 The results of 
the randomized phase II portion of the trial are reported here. 
Because this trial was initiated before the observation that 
pemetrexed offers a survival advantage in patients with non-
squamous histology relative to squamous histology,22,23 this 
trial initially enrolled patients with all histologies. Following 
these reports, a protocol amendment subsequently excluded 
patients with squamous histology.
PATIENTS AND METHODS
Patient Eligibility
Men and women (≥18 years old) with measurable 
stage IIIA or IIIB (without pleural effusion) NSCLC24 were 
eligible. Initially, all histologies were allowed, but based on 
subset analyses from clinical trials of pemetrexed as first- and 
second-line therapy for stage IV NSCLC,19,22,23,25 the protocol 
was amended in October 2008 to exclude patients with squa-
mous histology. Other key eligibility criteria were Eastern 
Cooperative Oncology Group performance status of 0 to 1, 
weight loss less than 10% in the 3 months before diagnosis, a 
forced expiratory volume in 1 second of greater than 1000 ml, 
and written informed consent.
Key exclusion criteria were prior tumor resection; prior 
chemotherapy for this cancer; prior RT for any thoracic or neck 
condition; symptomatic heart disease; myocardial infarction 
within the past 6 months; any pleural effusion on chest radio-
graph or computed tomography (CT) scan; planning target vol-
ume more than 3 liters; lung volume receiving more than 20 Gy 
greater than 40%; inability to discontinue nonsteroidal antiin-
flammatory drugs for 2 days before, the day of, and 2 days after 
pemetrexed; and unwillingness or inability to take folic acid, 
vitamin B
12
, or dexamethasone as required by protocol.
This study was conducted in accordance with the 
Declaration of Helsinki and good clinical practice guidelines. 
The protocol was approved by local Human Institutional 
Review Boards and in accordance with an assurance filed 
with and approved by the Department of Health and Human 
Services. Written informed consent was obtained.
Study Design and Treatment
This was an open-label, noncomparative, random-
ized trial. Per protocol, the two study treatment arms were 
analyzed independently. Patients were randomized (1:1) to 
arm A: pemetrexed 500 mg/m2 administered intravenously 
on day 1 followed by carboplatin area under the curve five 
intravenously on day 1, or to arm B: pemetrexed 500 mg/m2 
administered intravenously on day 1 followed by cisplatin 
75 mg/m2 on day 1. Both arms received chemotherapy every 
3 weeks for three cycles with concurrent RT at a dose of 2 
Gy per day administered 5 days a week to a total dose of 64 
to 68 Gy. Randomization was performed without stratifica-
tion factors.
Patients received consolidation pemetrexed 500 mg/
m2 every 3 weeks for three cycles after RT completion. 
Consolidation chemotherapy did not begin until the absolute 
neutrophil count was 1500 mm−3 or more and platelets were 
100,000 mm−3 or more. Subsequent cycles of therapy did not 
begin until absolute neutrophil count was 1000 mm−3 or more 
and platelets were 75,000 mm−3 or more. For hematologic tox-
icities, therapy could be held up to 28 days from day 1 of the 
previous cycle.
Patients received daily folic acid, beginning at least 
1 week before the first dose of pemetrexed, and continuing 
daily thereafter until 3 weeks after the last pemetrexed dose. 
Intramuscular vitamin B
12
 was begun at least 1 week before 
the first dose of pemetrexed and continued approximately 
every 9 weeks until 3 weeks after the last pemetrexed dose. 
Patients were premedicated with dexamethasone and received 
full supportive care. Prophylactic use of colony-stimulating 
factors was not permitted, but granulocyte-colony–stimulating 
factor and erythropoietin were allowed, if clinically indicated. 
Granulocyte-colony–stimulating factor was not administered 
on radiation days. Treatment was continued until protocol 
completion, disease progression, unacceptable toxicity, or dis-
continuation for other reasons. The ClinicalTrials.gov identi-
fier is NCT00482014.
Radiotherapy
Chest irradiation began on chemotherapy day 1. 
Radiotherapy was administered after chemotherapy. The total 
RT dose, which was calculated using algorithms accounting 
for tissue inhomogeneity, was 64 to 68 Gy. Treated volumes 
included the gross tumor volume plus margins, without elective 
nodal irradiation. A volumetric treatment planning CT study 
defined the gross tumor volume, clinical target volume, and 
planned target volume. Radiotherapy was administered in 2.0 
Gy fractions, 5 days per week. The suggested beam energy was 
6 to 10 MV, but investigators were permitted to use up to 18 MV.
If therapy interruption for 1 week or less was neces-
sary, irradiation was resumed and completed to the prescribed 
dose. If a longer interruption in therapy was required, treat-
ment resumption was at the radiation oncologist’s discretion.
Chemotherapy Dose Adjustments
For grade 3 and grade 4 hematologic toxicities, the 
protocol mandated holding chemotherapy until recovery and 
then resuming at 75% or 50% dose as specified. Radiotherapy 
was held week to week until recovery. If these events recurred 
after dose reduction, the patient was discontinued from study 
treatment. If RT was held, chemotherapy was also held. For 
hemoglobin 8 g/dl or less, the patient was transfused without 
treatment interruption.
For specified grade 3 or more nonhematologic toxici-
ties, chemotherapy was held up to 1 week until recovery to 
grade 1 or less and then resumed at the previous dose or a 
reduced dose depending on the toxicity. Radiotherapy was 
also held. Neurologic toxicities of grade 2 or more required 
holding platinum until recovery to grade 1 or less.
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Patient Evaluations
Tumors could be measured by CT or magnetic resonance 
imaging. The same assessment method was used throughout 
the study. During the study, tumor measurements were per-
formed at the investigator’s discretion during chemoradiation, 
within 7 to 10 days before the first dose of consolidation ther-
apy and after cycle 3 of consolidation. Tumor measurements 
were also performed at the 30-day follow-up assessment. All 
patients achieving an objective response had a 4-week confir-
mation scan.
Assessments, such as physical examinations, perfor-
mance status, hematology, blood chemistry, CTCAE Version 
3.0 grading, and concomitant medication recording, were per-
formed at prespecified intervals throughout the study. A late 
radiation morbidity assessment using the Radiation Therapy 
Oncology Group Late Morbidity Scoring Schema was per-
formed approximately 90 days after the start of RT.
On completion of all study therapy, patients had a 
30-day follow-up assessment including a tumor measurement. 
Thereafter, patients were followed monthly for 2 months, then 
every 2 months for 6 months, and then every 3 months until 
progression or for 24 months from initiation of study therapy, 
whichever came first. After progression, patients were fol-
lowed up every 3 months for survival.
Statistical Considerations
The primary objective was 2-year OS rate using 
Kaplan–Meier analyses.26 On the basis of SWOG 9504 yield-
ing a 54% 2-year survival rate,27 the threshold of interest for 
pursuing a phase III trial was 50%, and a 2-year survival of 
30% or lower was of no interest. Assuming that patients would 
be accrued within 18 months and observed an additional 24 
months, 46 patients per arm provided an approximate 82% 
power to detect a 2-year survival rate of 50% or more, with 
a one-sided significance level of 0.05 in each arm. To allow 
for a 10% ineligibility rate, 51 patients per arm were planned.
Secondary objectives were median OS, ORRs, time to 
disease progression, and toxicity and feasibility of these two 
regimens in this patient population. Time-to-event endpoints 
were analyzed using the Kaplan–Meier method.26 Response 
was measured according to Response Evaluation Criteria in 
Solid Tumors 1.0.28 Toxicities were graded using the CTCAE 
Version 3.0.29
The intent-to-treat (ITT) population included all 
enrolled (randomized) patients regardless of whether they 
received treatment. The safety population was all patients 
receiving 1 dose or more of pemetrexed plus carboplatin or 
cisplatin and 1 dose of radiotherapy.
FIGURE 1.  CONSORT diagram. Patient disposition is shown. The reasons for discontinuation of the two patients before receiv-
ing consolidation therapy in the PC arm were not reported. CRT, concurrent radiotherapy; PC, pemetrexed-cisplatin; PCb, 
pemetrexed-carboplatin.
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RESULTS
Patient Characteristics and Treatment
From June 2007 to November 2009, 98 patients were 
enrolled (46 PCb; 52 PC) in 17 centers located in the United 
States and India. Patients were followed until October 2011. 
Figure 1 shows the CONSORT diagram. Table 1 shows base-
line demographics. Notably, 13 patients (28.3%) in the PCb 
arm and 11 patients (21.2%) in the PC arm had squamous 
histology.
Efficacy
In the ITT population, the 2-year OS rates were 45.4% 
(95% confidence interval [CI], 29.5–60.0) and 58.4% (95% 
CI, 42.6–71.3) with PCb and PC, respectively (Fig. 2 and 
Table 2). The median OS was 18.7 months for PCb (95% 
CI, 12.9–not evaluable [NE]) and 27.0 months for PC (95% 
CI, 23.2–NE). In nonsquamous patients, median OS was NE 
in either arm, whereas the 2-year survival rates were 48.0% 
(95% CI, 29.0–64.8) and 55.8% (95% CI, 38.0–70.3) with 
PCb and PC, respectively.
The ORRs were 52.2% (complete response, 6.5%; 
partial response, 45.7%) with PCb and 46.2% (complete 
response, 3.8%; partial response, 42.3%) with PC (Table 2). 
In nonsquamous patients, the ORR was 54.5% with PCb and 
39.0% with PC.
The median time to progression was 8.8 months (95% 
CI, 6.0–12.6) with PCb and 13.1 months (95% CI, 8.3–NE) 
with PC (Fig. 3 and Table 2).
Drug Exposure
All enrolled patients received 1 dose or more of PCb 
or PC. Forty-two PCb-treated (91.3%) and 40 PC-treated 
(76.9%) patients completed chemoradiotherapy. Thirty-eight 
PCb-treated (82.6%) and 35 PC-treated (67.3%) patients 
received consolidation therapy. Table 3 shows drug exposure 
during the chemoradiotherapy and consolidation periods.
During the concurrent RT phase, the median (range) 
actual doses received were 66.0 Gy (34.0–74.0) and 66.0 Gy 
(0–84.7) in the PCb and PC arms, respectively. One patient in 
the PCb arm and three patients in the PC arm did not receive 
TABLE 1.  Baseline Demographics (ITT Population)
Parameter
PCb
(N = 46)
PC
(N = 52)
Sex, n (%)
  Female 16 (34.8) 21 (40.4)
  Male 30 (65.2) 31 (59.6)
Age, yr
  Median (range) 62.8 (43.7–82.4) 64.3 (45.8–85.2)
Race, n (%)
  African 5 (10.9) 5 (9.6)
  White 36 (78.3) 37 (71.2)
  Hispanic 1 (2.2) 0 (0.0)
  Asian 4 (8.7) 10 (19.2)
Primary tumor diagnosis, n (%)
  Adenocarcinoma 19 (41.3) 18 (34.6)
  Large cell 3 (6.5) 3 (5.8)
  Mixed histology 0 (0.0) 2 (3.8)
  Poorly differentiated 
NSCLC
9 (19.6) 13 (25.0)
  Squamous cell 13 (28.3) 11 (21.2)
  Other 2 (4.3) 5 (9.6)
Disease stage
  Stage IIIA 20 (43.5) 27 (51.9)
  Stage IIIB 26 (56.5) 25 (48.1)
ITT, intent-to-treat; N = total population size; n = number of patients; PC, pemetrexed/
cisplatin; PCb, pemetrexed/carboplatin; NSCLC, non–small-cell lung cancer.
FIGURE 2.  Kaplan–Meier plot of 
overall survival. Overall survival was 
defined as the duration from date of 
randomization to date of death as 
the result of any cause. Censoring 
was done on the date the patient was 
last known to be alive, for patients 
who were still alive at the date of 
the last follow-up visit. Confidence 
intervals (CI) are based on the 
binomial distribution. Kaplan–Meier 
analyses were performed for the 
2-year survival rate. NE, not evalu-
able; PC, pemetrexed-cisplatin; PCb, 
pemetrexed-carboplatin; *Censured 
patients.
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any RT. Interruptions of RT occurred in 39.1% of PCb-treated 
patients and 46.2% of PC-treated patients. Reasons for dose 
interruptions were adverse events (AEs) (19.6% PCb; 13.5% 
PC), equipment failure (19.6% PCb; 7.7% PC), and patient 
decision (15.2% PCb; 26.9% PC). According to responses to 
a questionnaire administered to patients, 26 patients (56.5%) 
in the PCb arm and 25 patients (48.1%) in the PC arm com-
pleted RT with the total planned dose administered; approxi-
mately half of the patient population did not answer this 
questionnaire.
Safety
Most patients experienced one or more possibly drug-
related treatment-emergent AE (PCb, 89.1%; PC, 73.1%); 
approximately half of patients experienced one or more pos-
sibly drug-related grade 3 or grade 4 treatment-emergent AE 
(PCb, 50%; PC, 42.3%). Possibly drug-related serious AEs 
(SAEs) were experienced by 23.9% and 17.3% of patients in 
the PCb and PC arms, respectively. Drug-related SAEs occur-
ring in 3% or more of patients in the PCb arm were: nausea 
(6.5%), vomiting (6.5%), dehydration (6.5%), anemia (4.3%), 
thrombocytopenia (4.3%), dysphagia (4.3%), and esophagi-
tis (4.3%). Drug-related SAEs occurring in 3% or more of 
patients in the PC arm were: dehydration (7.7%), hypotension 
(5.8%), esophagitis (3.8%), and vomiting (3.8%).
Possibly drug-related AEs leading to discontinuation 
were experienced by one patient (2.2%) in the PCb arm (grade 
3 respiratory failure) and four patients (7.7%) in the PC arm 
TABLE 2.  Summary of Efficacy (ITT Population)
Parameter
Objective Tumor Responsea
PCb PC
All
N = 46
Nonsquamous
N = 33
All
N = 52
Nonsquamous
N = 41
Tumor response rate, n (%) 24 (52.2) 18 (54.5) 24 (46.2) 16 (39.0)
Complete response, n (%) 3 (6.5) 2 (6.1) 2 (3.8) 2 (4.9)
Partial response, n (%) 21 (45.7) 16 (48.5) 22 (42.3) 14 (34.1)
Stable disease, n (%) 15 (32.6) 10 (30.3) 18 (34.6) 17 (41.5)
Progressive disease, n (%) 1 (2.2) 0 (0) 6 (11.5) 5 (12.2)
Unknown, n (%) 6 (13.0) 5 (15.2) 4 (7.7) 3 (7.3)
Time to event
2-yr overall survival rate, % (95% CI) 45.4 (29.5–60.0) 48.0 (29.0–64.8) 58.4 (42.6–71.3) 55.8 (38.0–70.3)
Median overall survival, mo (95% CI) 18.7 (12.9–NE) 22.8 (14.0–NE) 27.0 (23.2–NE) 25.9 (14.5–NE)
Median time to disease progression, mo (95% CI) 8.8 (6.0–12.6) 9.0 (6.3–16.4) 13.1 (8.3–NE) 12.9 (7.8–NE)
aResponse was determined per RECIST criteria.
CI, confidence interval; ITT, intent to treat; N, number in group; N, population size; NE, not evaluable; PC, pemetrexed/cisplatin; PCb, pemetrexed/carboplatin; RECIST, Response 
Evaluation in Solid Tumors.
FIGURE 3.  Kaplan–Meier plot of 
time to progression. Time to progres-
sion was measured from randomiza-
tion to the first observation of disease 
progression according to Response 
Evaluation Criteria in Solid Tumors. 
CI, confidence interval; NE, not 
evaluable; PC, pemetrexed-cisplatin; 
PCb, pemetrexed-carboplatin; TTP, 
time to progression; *Censored 
patients.
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(grade 3 gastritis, grade 2 reduced renal creatinine clearance, 
and 2 cases of grade 3 renal failure). In addition, one patient 
in the PC arm discontinued because of a possibly drug-related 
SAE (grade 5 myocardial infarction) during the consolidation 
phase.
Table 4 shows grade 3 and grade 4 AEs that were possi-
bly related to study drug. A higher percentage of PCb-treated 
patients (19.6%) than PC-treated patients (7.7%) required 
transfusions. With the exception with of one patient in the 
PCb arm requiring platelets, all transfusions were of packed 
red blood cells. The arms had similar hospitalization rates 
(PCb, 30.4%; PC, 28.8%).
During study treatment, one patient (2.2%) in the PCb 
arm died from disease progression and four patients (7.7%) 
in the PC arm died: one patient (1.9%) from disease progres-
sion, two (3.8%) from AEs, and one (1.9%) from non–study-
related causes. The two deaths caused by AEs in the PC arm 
occurred during the consolidation period: one because of dys-
pnea (not related to study drug), and one because of possibly 
drug-related myocardial infarction.
Poststudy Therapy
Both arms had similar rates of patients receiving any 
poststudy therapy (PCb, 41.3%; PC, 42.3%). Poststudy sur-
gery (unspecified) was received by 6.5% of PCb-treated and 
13.5% of PC-treated patients. Poststudy chemotherapy was 
received by 21.7% of PCb-treated and 36.5% of PC-treated 
patients. The proportions of patients receiving poststudy RT 
were similar (PCb, 17.4%; PC, 19.2%) in both arms.
DISCUSSION
On the basis of clinical trials showing that chemoradio-
therapy was superior to thoracic RT,30–33 combined modality 
treatment has emerged as the standard of care for patients with 
unresectable stage III NSCLC with adequate performance sta-
tus.2,30 Currently, concurrent cisplatin/etoposide/RT or carbo-
platin/paclitaxel/RT are the frequently used regimens.3,12,34–37 
Despite improved survival with chemoradiotherapy relative 
to RT alone, outcomes are still poor, and modern chemora-
diotherapy regimens are associated with significant toxicities. 
Therefore, there is a need for more efficacious regimens with 
improved toxicity profiles.
Here, we report the results of a randomized phase II 
trial studying pemetrexed in combination with carboplatin 
or cisplatin and RT followed by pemetrexed consolidation. 
Pemetrexed has radiosensitizing activity in vitro and in 
xenografts, and it has been well tolerated when combined 
with platinum in patients with NSCLC.6–17 In this trial, the 
2-year OS rates were 45.4% and 58.4% with PCb and PC, 
respectively. The PC arm exceeded the prespecified criteria 
of a 2-year survival rate of 50% needed to proceed to a phase 
III trial. Other phase I–II trials having doses and schedules 
similar to this trial have tested pemetrexed in combination 
with platinum and RT10–17,21,38; among these, there has only 
been one randomized trial (pemetrexed, carboplatin, and 
RT with and without cetuximab).12 These prior trials have 
demonstrated the tolerability and efficacy of pemetrexed 
in combination with platinum and RT. Our trial is notable 
because it sought to examine dose delivery and safety of PC 
TABLE 3.  Drug Exposure
Chemoradiation Consolidation
PCb PC PCb PC
P (N = 46) Cb (N = 46) P (N = 52) C (N = 52) PCb (N = 38) PC (N = 35)
Patients completing  
at least one cyclea
46 (100) 46 (100) 52 (100) 52 (100) 38 (100) 35 (100)
Patients completing  
at least two cyclesa
46 (100) 46 (100) 46 (88.5) 46 (88.5) 38 (100) 34 (97.1)
Patients completing  
at least three cyclesa
42 (91.3) 42 (91.3) 42 (80.8) 42 (80.8) 35 (92.1) 28 (80.0)
Mean number of cycles  
received (SD)
2.9 (0.28) 2.9 (0.28) 2.7 (0.67) 2.7 (0.67) 2.9 (0.3) 2.8 (0.5)
Patients with dose  
adjustments, n (%)
5 (10.9) 5 (10.9) 7 (13.5) 7 (13.5) 5 (13.2) 6 (17.1)
  Dose omissions 1 (2.2) 1 (2.2) 2 (3.8) 1 (1.9) 0 (0) 2 (5.7)
  Dose reductions 4 (8.7) 4 (8.7) 6 (11.5) 6 (11.5) 5 (13.2) 4 (11.4)
Actual mean dose (SD)b,c 162.3 (11.5) 1.6 (0.2) 160.4 (14.9) 24.1 (2.3) 161.6 (15.5) 157.7 (21.1)
Planned mean doseb,c 166.7 1.7 166.7 25.0 166.7 166.7
Dose intensityd
  Mean (SD) 97.4 (6.9) 98.8 (13.4) 96.2 (8.9) 96.5 (9.2) 97.0 (9.3) 94.6 (12.6)
  Median (range) 100 (67.3–103.3) 99.5 (58.5–125.0) 100.0 (52.1–102.6) 99.9 (52.1–111.5) 100.0 (49.8–111.1) 99.4 (50.3–101.7)
aNumber of cycles is calculated as number of days on drug divided by 21 days and then rounded to a whole number.
bFor each patient, the actual mean dose is calculated as the dose received divided by number of weeks on treatment; the planned mean dose is same for all patients according to 
the protocol.
cFor pemetrexed and cisplatin, the unit is mg/m2/week; for carboplatin, the unit is area under the curve/week.
dDose intensity is calculated as mean dose received/mean dose planned × 100.
C, cisplatin; Cb, carboplatin; n, number in group; N, population size; P, pemetrexed; PC, pemetrexed/cisplatin; PCb, pemetrexed/carboplatin.
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and PCb in the setting of uniform entry criteria and radio-
therapy plan.
When this trial was planned, the preferential efficacy 
of pemetrexed in patients with nonsquamous histology22,23 
was not known. A substantial percentage of patients with 
squamous histology (PCb, 28.3%; PC, 21.2%) were enrolled 
before a protocol amendment excluding squamous patients. In 
the PC arm, the prespecified 2-year survival rate of 50% was 
exceeded regardless of whether the ITT (58.4%) or nonsqua-
mous (55.8%) population was considered. In the PCb arm, the 
2-year survival rate in patients with nonsquamous histology 
was 48% and was 45.4% in the ITT population. The results 
for both the ITT and nonsquamous populations of PC-treated 
patients are consistent with the 2-year survival rate of 54% 
obtained in the phase 2 SWOG 9504 trial with cisplatin/eto-
poside/concurrent RT plus consolidation docetaxel27 and with 
the 2-year survival rate (57.5%) obtained in a small phase 1 
trial testing cisplatin/pemetrexed/concurrent RT plus consoli-
dation pemetrexed.11
In patients with nonsquamous histology, median OS 
was not reached in either arm. In the ITT population, median 
OS rates were 18.7 months and 27.0 months with PCb and 
PC, respectively. Median OS in the PC arm was numerically 
superior to the updated median OS of 21.5 months reported 
for the entire study population of the LUN 01-24 trial (con-
current etoposide/cisplatin/RT with or without consolidation 
docetaxel).39
In the phase III LUN 01-24 trial, which was terminated 
for futility because of lack of benefit, a regimen of cisplatin + 
etoposide + RT followed by docetaxel consolidation was 
associated with considerable grades 3 through 5 toxicity 
(chemoradiotherapy/consolidation): 32.0%/24.7% grade 
3 or grade 4 neutropenia, 9.9%/10.9% grade 3 or grade 4 
febrile neutropenia, 17.2%/not determined esophagitis, and 
not determined/9.6% grades 3 through 5 pneumonitis.34 In 
contrast, the rates of drug-related grade 3 and grade 4 neutro-
penia (13.4%), grade 3 and grade 4 febrile neutropenia (0%), 
grade 3 radiation pneumonitis (1.9%), grade 3 and grade 4 
esophagitis (5.7%), and grade 3 radiation esophagitis (1.9%) 
in the PC arm for the entire treatment period in this trial seem 
lower.
The data here also show that both PCb and PC are fea-
sible. The mean dose intensities for the chemoradiotherapy 
and consolidation periods were more than 94% for each drug, 
allowing full dose delivery of planned systemic treatment in 
combination with therapeutic doses of radiotherapy. In this 
trial, 91.3% of PCb-treated patients and 76.9% of PC-treated 
patients completed chemoradiotherapy, whereas in SWOG 
9504, 88% of patients completed chemoradiotherapy.27
This trial has a number of limitations. One limitation 
is that the enrollment criteria was changed mid study from 
patients with all histologies to those with nonsquamous 
tumors. Another limitation of this study is that it was not 
designed to test the role of consolidation therapy. This study is 
further limited by a small sample size and a statistical design 
that did not allow between-arm comparisons to be performed. 
As such, this study does not answer the carboplatin versus 
cisplatin question, nor does it allow comparison of the tested 
TABLE 4.  Grades 3 and 4 Adverse Events, Possibly Related 
to Study Drug (Safety Population)
PCb
(N = 46)
PC
(N = 52)
Grade 3
n (%)
Grade 4
n (%)
Grade 3
n (%)
Grade 4
n (%)
Hematologic
  Anemia 5 (10.9) 0 (0.0) 3 (5.8) 1 (1.9)
  Febrile neutropenia 2 (4.3) 0 (0.0) 0 (0.0) 0 (0.0)
  Leukopenia 5 (10.9) 0 (0) 4 (7.7) 0 (0)
  Lymphopenia 3 (6.5) 0 (0.0) 1 (1.9) 0 (0.0)
  Neutropenia 7 (15.2) 3 (6.5) 5 (9.6) 2 (3.8)
  Thrombocytopenia 2 (4.3) 2 (4.3) 2 (3.8) 1 (1.9)
Nonhematologic
  Alanine  
aminotransferase  
increased
1 (2.2) 0 (0.0) 0 (0.0) 0 (0.0)
  Anorexia 0 (0.0) 0 (0.0) 2 (3.8) 0 (0.0)
  Aspartate  
aminotransferase  
increased
1 (2.2) 0 (0.0) 0 (0.0) 0 (0.0)
  Asthenia 0 (0.0) 0 (0.0) 2 (3.8) 0 (0.0)
  Bronchitis 1 (2.2) 0 (0.0) 0 (0.0) 0 (0.0)
  Decreased appetite 0 (0.0) 0 (0.0) 1 (1.9) 0 (0.0)
  Dehydration 3 (6.5) 0 (0.0) 5 (9.6) 0 (0.0)
  Diarrhea 0 (0.0) 0 (0.0) 1 (1.9) 0 (0.0)
  Dysphagia 1 (2.2) 0 (0.0) 0 (0.0) 0 (0.0)
  Dyspnea 0 (0.0) 0 (0.0) 1 (1.9) 0 (0.0)
  Esophagitis 2 (4.3) 0 (0.0) 2 (3.8) 1 (1.9)
  Failure to thrive 0 (0.0) 0 (0.0) 1 (1.9) 0 (0.0)
  Fatigue 3 (6.5) 0 (0.0) 2 (3.8) 0 (0.0)
  Gastritis 0 (0.0) 0 (0.0) 1 (1.9) 0 (0.0)
  Herpes esophagitis 0 (0.0) 0 (0.0) 1 (1.9) 0 (0.0)
  Hyperbilirubinemia 1 (2.2) 0 (0.0) 0 (0.0) 0 (0.0)
  Hypokalemia 3 (6.5) 0 (0.0) 2 (3.8) 0 (0.0)
  Hyponatremia 1 (2.2) 0 (0.0) 2 (3.8) 0 (0.0)
  Hypotension 2 (4.3) 0 (0.0) 4 (7.7) 0 (0.0)
  Localized infection 1 (2.2) 0 (0.0) 0 (0.0) 0 (0.0)
  Mediastinitis 1 (2.2) 0 (0.0) 1 (1.9) 0 (0.0)
  Mucosal inflammation 0 (0.0) 0 (0.0) 1 (1.9) 0 (0.0)
  Muscular weakness 0 (0.0) 0 (0.0) 1 (1.9) 0 (0.0)
  Nausea 2 (4.3) 0 (0.0) 1 (1.9) 0 (0.0)
  Neuropathy peripheral 1 (2.2) 0 (0.0) 0 (0.0) 0 (0.0)
  Orthostatic hypotension 0 (0.0) 0 (0.0) 1 (1.9) 0 (0.0)
  Pneumonia 0 (0.0) 0 (0.0) 1 (1.9) 0 (0.0)
  Radiation esophagitis 0 (0.0) 0 (0.0) 1 (1.9) 0 (0.0)
  Radiation pneumonitis 1 (2.2) 0 (0.0) 1 (1.9) 0 (0.0)
  Renal failure 0 (0.0) 0 (0.0) 1 (1.9) 0 (0.0)
  Renal failure acute 0 (0.0) 0 (0.0) 1 (1.9) 0 (0.0)
  Respiratory failure 1 (2.2) 0 (0.0) 0 (0.0) 0 (0.0)
  Syncope 1 (2.2) 0 (0.0) 0 (0.0) 0 (0.0)
  Vomiting 2 (4.3) 0 (0.0) 3 (5.8) 0 (0.0)
  Weight decreased 1 (2.2) 0 (0.0) 0 (0.0) 0 (0.0)
n, number in group; N, population size; PC, pemetrexed/cisplatin; PCb, pemetrexed/
carboplatin.
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regimens to more established regimens such as cisplatin/eto-
poside or carboplatin/paclitaxel.
In conclusion, the 2-year OS rates were 45.4% (95% 
CI, 29.5–60.0) for PCb and 58.4% (95% CI, 42.6–71.3) for 
PC. Because of study design, no conclusions regarding the 
relative efficacy of these regimens can be made, although 
both combinations with concurrent RT were active and well 
tolerated.
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